In this prospective PMS study of encorafenib plus binimetinib combination therapy in Japanese patients with BRAF-mutant unresectable malignant melanoma, no new safety concerns were reported when compared with results from the global phase III, COLUMBUS trial [8]. Here, BRAF is linked to melanoma.